HelsingborgApotek.com

Apotheek Holland NL

Apotheek Utrecht NL

Publications and related articles about us and the wound care industry

European KOLs Initiate NAZARÉ Post-Market Clinical Study

23 Jan 2026

European wound care key opinion leaders initiate NAZARÉ, an investigator-initiated post-market study evaluating COMS® therapy across Europe.

Read more
European KOLs Initiate NAZARÉ Post-Market Clinical Study
FDA Breakthrough Device Designation for COMS® One Therapy System

18 Sep 2025

Piomic Medical Receives FDA Breakthrough Device Designation for its novel COMS® One Therapy System.

Read more
FDA Breakthrough Device Designation for COMS® One Therapy System
MAVERICKS IDE Trial Protocol Published in WOUNDS by Leading U.S. Experts

29 Aug 2025

MAVERICKS study sets new standards in the wound-care industry amid major reimbursement changes.

Read more
MAVERICKS IDE Trial Protocol Published in WOUNDS by Leading U.S. Experts
Piomic Medical Secures Eurostars Financing for COMS® Blue

14 Mar 2025

Piomic Medical secures Eurostars funding for COMS® Blue, advancing antibiotic-independent wound infection treatment with real-time diagnostics and digital health.

Read more
Piomic Medical Secures Eurostars Financing for COMS® Blue
Piomic Medical Wins EPUAP 2024 Most Innovative Product Award

04 Oct 2024

Award highlights promising potential of COMS® therapy for severe pressure ulcers, with off-label data showing “clinically significant rates of wound area reduction and wound closure“1.

Read more
Piomic Medical Wins EPUAP 2024 Most Innovative Product Award
New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care

23 Aug 2024

New Study highlights COMS® as a promising tool for debridement and wound bed preparation for other therapies, such as skin grafts.

Read more
New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care
Piomic Medical Announces First Patients Enrolled in MAVERICKS Study Sites

03 Sep 2023

Trial seeks to assure Piomic’s COMS® treatment is safe and effective in therapy-refractory diabetic foot ulcers

Read more
Piomic Medical Announces First Patients Enrolled in MAVERICKS Study Sites
Don't miss our updates!
You must complete your email.
You must accept our Privacy Policy